Benjamin F. Edwards & Company Inc. Grows Position in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN)

Benjamin F. Edwards & Company Inc. raised its position in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) by 11.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 50,150 shares of the company’s stock after acquiring an additional 5,100 shares during the quarter. Benjamin F. Edwards & Company Inc. owned approximately 0.45% of CollPlant Biotechnologies worth $320,000 as of its most recent SEC filing.

Separately, Villere ST Denis J & Co. LLC lifted its position in shares of CollPlant Biotechnologies by 20.4% during the 4th quarter. Villere ST Denis J & Co. LLC now owns 361,293 shares of the company’s stock worth $2,309,000 after purchasing an additional 61,120 shares during the last quarter. Institutional investors and hedge funds own 21.69% of the company’s stock.

CollPlant Biotechnologies Stock Up 8.2 %

CLGN stock opened at $6.75 on Friday. The stock has a market cap of $77.31 million, a price-to-earnings ratio of -10.55 and a beta of 0.23. CollPlant Biotechnologies Ltd. has a fifty-two week low of $4.22 and a fifty-two week high of $8.90. The business has a 50 day moving average price of $5.37 and a 200 day moving average price of $5.48.

CollPlant Biotechnologies (NASDAQ:CLGN) last issued its earnings results on Thursday, April 4th. The company reported ($0.42) earnings per share (EPS) for the quarter. CollPlant Biotechnologies had a negative net margin of 64.05% and a negative return on equity of 22.17%. The company had revenue of $0.30 million during the quarter. As a group, sell-side analysts anticipate that CollPlant Biotechnologies Ltd. will post -1.42 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of CollPlant Biotechnologies in a research note on Friday, April 5th.

CollPlant Biotechnologies Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.